Of note, an increasing number of randomized clinical trials are being conducted and have revealed the promising effects of anlotinib together with EFGR-TKIs, including icotinib (Zhang et al., 2023), erlotinib (Chu et al., 2022), gefitinib (Zhang et al., 2021), osimertinib (Han et al., 2022), and almoertinib (Chen et al., 2023), for untreated EGFR-positive NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.